HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.

Abstract
A series of novel ferulic acid-O-alkylamines derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. In vitro studies displayed that all the synthesized target compounds showed impressive inhibitory activity against butyrylcholinesterase (BuChE), significant inhibition/disaggregation of self-induced β-amyloid (Aβ) aggregation and acted as potential antioxidants. Particularly, compound 7f, one of the most potent BuChE inhibitor (IC50 value of 0.021 μM for equine serum BuChE, 8.63 μM for ratBuChE and 0.07 μM for human serum BuChE), was found to be a good acetylcholinesterase (AChE) inhibitor (IC50 = 2.13 μM for electric eel AChE, 1.8 μM for ratAChE and 3.82 μM for human erythrocytes AChE), and the result of molecular docking provided an explanation for its selective BuChE inhibitory activity. Compound 7f also had noteworthy inhibitory effects on self-induced Aβ1-42 aggregation (50.8 ± 0.82%) and was found to disaggregate self-induced Aβ1-42 aggregation (38.7 ± 0.65%), which was further elucidated by the transmission electron microscopy. Meanwhile, compound 7f showed the modest antioxidant activity (0.55 eq of Trolox), good protective effect against H2O2-induced PC12 cell injury, with low toxicity. Moreover, compound 7f could cross the blood-brain barrier (BBB) in vitro. Significantly, compound 7f did not exhibit any acute toxicity in mice at doses up to 1000 mg/kg, and the step-down passive avoidance test showed this compound significantly reversed scopolamine-induced memory deficit in mice. Taken together, the results indicated that compound 7f is a very promising multifunctional agent in the treatment of Alzheimer's disease, particularly the advanced stages of AD.
AuthorsZhipei Sang, Wanli Pan, Keren Wang, Qinge Ma, Lintao Yu, Yan Yang, Ping Bai, Chaoliang Leng, Qian Xu, Xiaoqing Li, Zhenghuai Tan, Wenmin Liu
JournalEuropean journal of medicinal chemistry (Eur J Med Chem) Vol. 130 Pg. 379-392 (Apr 21 2017) ISSN: 1768-3254 [Electronic] France
PMID28279845 (Publication Type: Journal Article)
CopyrightCopyright © 2017 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Amyloid beta-Peptides
  • Antioxidants
  • Cholinesterase Inhibitors
  • Coumaric Acids
  • ferulic acid
  • Butyrylcholinesterase
Topics
  • Alzheimer Disease (drug therapy)
  • Amyloid beta-Peptides (drug effects)
  • Animals
  • Antioxidants
  • Blood-Brain Barrier (metabolism)
  • Butyrylcholinesterase (drug effects)
  • Cholinesterase Inhibitors (chemistry, pharmacology)
  • Coumaric Acids (chemistry, pharmacology)
  • Drug Design
  • Eels
  • Humans
  • Memory Disorders (drug therapy)
  • Mice
  • PC12 Cells
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: